Cambridge Cardiac Care Centre

Our Research Studies

Want to enrol in a clinical trial?

Participating in a clinical research study provides exciting opportunities to be a part of history in the making as well as providing unique access to novel technologies and therapies that are not otherwise available to patients at large. It does, however, require thoughtful consideration. Talk with your doctor and family members before deciding to enrol. Either you or your doctor may contact our research staff for more information and to discuss any studies that may be suitable for you specifically.

Wave graphic Pexels chokniti khongchum 2280547

BRAIN AF: Treating the heart, Helping the brain

A study involving patients with Atrial Fibrillation and a CHADS2 score of 0. with a goal of reducing stroke, transient ischemic attack (TIA) and neurocognitive decline. To participate in this study, you must: Have a diagnosis of atrial fibrillation; Be between 30 and 62 years old; Absence of arterial hypertension; diabetes,…

Wave graphic P1080068

CORALreef Outcomes (MK-0616-015): oral PCSK9 Inhibitor in refractory hyperlipidemia and cardiovascular events

Assessing MK-0616, an oral PCSK9 inhibitor, in participants with high cardiovascular risk and LDL cholesterol refractory to Statins on major adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent arterial…

Wave graphic Pexels pixabay 208518

HERMES: Ziltivekimab in People With Heart Failure and Inflammation

Ziltivekimab is a human monoclonal antibody that works by reducing inflammatory responses within the body. Ziltivekimab has the potential to reduce inflammation in patients with HF, and consequently may reduce symptoms, as well as long-term morbidity and mortality. Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.)…

Wave graphic ECG

OCEAN(a) - Outcomes Trial: Effects of Olpasiran To reduce Lipoprotein (a) and impact on Cardiovascular Events

The primary objective of this study is to compare the effect of treatment with olpasiran on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Wave graphic 074939

OCEANIC-AF: Asundexian Compared to Apixaban to Prevent Stroke or Systemic Embolism in Atrial Fibrillation

Asundexian belongs to an emerging class of medicines known as factor XIa inhibitors, which are viewed as potentially safer and more effective alternatives to new oral anticoagulants (NOACs). Factor XI is a protein in the blood that is converted into its active enzyme form (factor XIa) as part of the blood coagulation cascade. Inhibiting factor…

Wave graphic IMG 1799

Realize-K: Sodium Zirconium Cyclosilicate (SZC) for the management of Hyperkalemia in patients with congestive heart failure

A study involving patients with symptomatic Heart Failure with reduced Ejection Fraction and Receiving Spironolactonehase IV. This double-blind, placebo-controlled, randomized-withdrawal trial evaluates the use of Sodium Zirconium Cyclosilicate (SZC) for the management of Hyperkalemia in patients with reduced ejection fraction heart failure who…

Wave graphic 080136

Redefine: Effects of CagriSema in People Living With Obesity and Diseases in the Heart and Blood Vessels

You may be able to take part if:

  • You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (peripheral arterial disease, or PAD)
  • You are 55 years of age or older
  • You are living with obesity (BMI over 30)
Wave graphic P1010798

REFINE ICD: the use of prophylactic ICD therapy to reduce the risk of sudden cardiac death in patients with LVEF between 36% to 50%

A study involving heart attack patients who have reduced heart pumping function (LVEF between 36% to 50%). This international, multi-centre trial assesses the use of prophylactic ICD therapy to reduce the risk of sudden cardiac death.

Wave graphic Medical equipment 2021 08 30 06 54 00 utc

SOS AMI: assessing the efficacy of selatogrel when self-administered to prevent recurrent heart attacks

Assessing the clinical efficacy of self administered selatogrel upon recurrence of an acute myocardial infarction (AMI). Eligibility Requirements: ≥ 18 years old within 4 weeks of a type 1 AMI (STEMI or NSTEMI).

Wave graphic 074939

SYNCHRONIZE-CVOT, survodutide on Obesity and heart disease risk

Study of survodutide in people with obesity / overweight with cardiovascular disease, chronic kidney disease or risk factors for heart disease. Inclusion Criteria:-BMI ≥27 kg/m2 with established heart disease and/or at least 2 weight related complications OR -participants with BMI ≥30 kg/m2 with established heart or kidney…

Wave graphic Katie at computer with treadmill in shot

VICTOR: Vericiguat in patients with reduced ejection fraction heart failure

A study involving adults with chronic Heart Failure with reduced Ejection Fraction. This pivotal phase 3, randomized, placebo-controlled, clinical study evaluates the efficacy and safety of the sGC Stimulator Vericiguat/MK-1242 in patients with reduced ejection fraction heart failure on optimum medical therapy.

Wave graphic Bill oxford 8u 2im Ja V Qs unsplash

DELIVER

A phase 3 study assessing the impact of Dapagliflozin, an SGLT2 inhibitor, on reduction of cardiovascular events and worsening heart failure in patients with heart failure with preserved ejection fraction. This study is finished enrolling and is in follow-up.

Wave graphic P1080062

Empa Kidney

A randomized, double-blind, placebo-controlled trial of Empagliflozin in people with chronic kidney disease, with or without diabetes, to assess if Empagliflozin reduces the risk of kidney disease progression or cardiovascular death. This study is finished enrolling and is in follow-up.

Wave graphic Katie at computer with treadmill in shot

Esperion

A randomized, double-blind, placebo-controlled study to assess the effects of Bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in statin intolerant patients with, or at high risk of developing, cardiovascular disease. This study is finished enrolling and is in follow-up.

Wave graphic P1070005

Finearts

A study involving HFpEF, Heart Failure patients with an ejection fraction greater than or equal to 40%. This randomized, double-blind, double-dummy, multi-centre Phase 3 clinical trial studies the efficacy and safety of Finerenone, taken once daily. The study monitors effects on symptoms, morbidity and mortality reduction.

Wave graphic Pexels pixabay 208518

SELECT

A phase 3 study assessing the impact of Semaglutide, a GLP1 receptor agonist, on weightloss and the recurrence of cardiovascular events in patients with atherosclerotic cardiovascular disease without diabetes. This study is finished enrolling and is in follow-up.

Wave graphic 074810

SURPASS

A phase 3 study assessing the effects of Tirzepatide, a GIP and GLP1 receptor agonist, in reducing future cardiovascular events in patients with diabetes and established cardiovascular disease . This study is finished enrolling and is in follow up.

  • (OSLER)Amgen

  • Accelerate

  • Active (A & I)

  • AIM HIGH

  • AKCEA

  • Alecardio

  • AlePrevent

  • ALOFT

  • Altitude

  • Amgen (Decartes)

  • Amgen (OSLER II )

  • Amgen Phase III (La Place II)

  • APPRAISE 2

  • Arise -Focus

  • Aristotle

  • Armada Registry

  • Assert II

  • Astronomer

  • ATLAS

  • Atmosphere

  • Averroes

  • Aware AF Program

  • Beautiful

  • BEST

  • BP EASE

  • CAIN

  • Camellia TIMI 61

  • CANTOS OLE

  • Carolina

  • Clarify Registry

  • Class Act

  • Cogentus

  • Cogentus con…

  • Commander

  • COMPASS LTOLE

  • Confidence 2

  • CTAF-2

  • CV Mobius Registry

  • CVEA 2303 **

  • Dal Outcomes Roche

  • Dal Plaque 2

  • Dapa HF Outcomes

  • DAR 311/ E

  • DECLARE ( TIMI 58 )

  • DELIGHT

  • DERIVE

  • Discovery

  • DM 71-05-01

  • DYSIS

  • Electra/DRONE

  • Emperor HF ( HFrEF )

  • Excel

  • Eze(stat) II

  • Ezetrol

  • FOCUS

  • Fourier (AMGEN )

  • FRESH

    A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled clinical trial studies the efficacy and safety of Firibistat (QGC001) as administered orally, twice daily, over 12 weeks to resistant-hypertension patients.

  • Galactic HF

  • GARFIELD Registry

  • Genetic AF

  • Gloria Registry

  • GOALProgram

  • HAT

  • Heart-Fid

    A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (Ferric Carboxymaltose) as treatment for Heart Failure with iron deficiency. This study is finished enrolling and is in follow-up.

  • HTN-A-Fib PILOT

  • I-Search

  • Improve-IT

  • INVESTED

  • Iris *fininshed**

  • ISH

  • Jupiter

  • LCZ696A 2201 US

  • LTOLE

  • LTS (Oydssey)

  • Mavik (TORY)

  • Merck 162 (Switch)

  • Merck 4448

  • NODE 302 ( open label )

  • NODE 303

    A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This multi-centre, open-label, Phase 3 study monitors the safety of Etripamil nasal spray for the termination of PSVT. Monitoring of symptoms is mostly completed remotely via an app on a mobile device.

  • Oberon/ Obelix

  • Odysseus

  • Odyssey Outcomes

  • PACT

  • Pallas

  • Pandora LCZ-

  • Paradigm

  • Paragon

  • PARASAIL

  • Pegasus -TIMI 54

  • PNAI_MNA_001

  • POWER

  • Prominent

    A randomized, double-blind, placebo-controlled, event-driven efficacy and safety study to assess if Pemafibrate reduces cardiovascular outcomes by reducing triglycerides in patients with diabetes. This study is finished enrolling and is in follow-up

  • RAPID NODE 301

    A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This double-blind, placebo-controlled, phase 3 trial studies the efficacy and safety of Etripamil Nasal Spray for the termination of PSVT. This study requires a test dose to be admisnisterd in-clinic at randomization to be enrolled.

  • RE-LY

  • Reached

  • React Program

  • REDEEM

  • REFRESH

    A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled and open-label clinical trial studies the efficacy and long-term safety of Firibistat (QGC001) as administered orally, once daily.

  • RELY-ABLE

  • REVEAL - TIMI 55

  • Rocket 81408

  • RUBY 1

  • SAALT

  • SOLID- TIMI 52

  • Soloist

  • SPIRE 1

  • SPIRE 2

  • STEP HFpEF

    A study involving patients with obesity-related heart failure who have a preserved ejection fraction and do not have diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

  • STEP HFpEF DM

    A study involving patients with obesity-related heart failure who have a preserved ejection fraction and type 2 diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

  • Study 112 Elderly

  • Study 79 (Tempo)

  • Study 90 (EZEPATH)

  • Sure Registry (25)

  • TECOS (TIMI)

  • THEMIS

  • Tigris

  • Tigris

  • TIGRIS REGISTRY

  • TRA 2PB

  • Tranquility

  • VERTIS

  • VICTORIA

  • VICTORIA HF REGISTRY

  • Zerbini Registry